Understanding how the DEA classifies cannabis compounds is essential for patients and providers navigating the increasingly complex legal landscape between hemp, CBD, and controlled substances. The DEA has published an updated collection of cannabis-related regulatory and scheduling documents, providing a consolidated federal reference for the current legal classification and enforcement framework surrounding marijuana and hemp-derived cannabinoids. These documents detail the Controlled Substances Act scheduling criteria, enforcement guidance, and regulatory interpretations that shape how cannabis products are classified at the federal level.
D.C. Tightens Cannabis Ads and Virginia Moves Toward Adult-Use Sales
The DMV cannabis landscape is evolving fast: D.C.: Tightening ads — limiting youth exposure, content rules Virginia: Building retail framework — July applications, Nov sales One jurisdiction refining. One building from scratch. Both navigating the same federal uncertainty. Progress looks different everywhere. But it’s all progress. Outlaw Report covers two significant developments in the DMV cannabis landscape. Washington D.C.
Cannabis Rescheduling Update: Advocates Eye AG Bondi Hearing for Status Report
Cannabis rescheduling could ease research restrictions and reduce tax burdens on the industry, but it won’t make recreational marijuana legal—only Congress can do that. Reform advocates are watching Attorney General Pam Bondi’s scheduled appearance before the House Judiciary Committee for an update on where cannabis rescheduling stands. Pennsylvania House Democrats are calling on the GOP Senate to follow their lead on legalization, as Gov.
FDA Misses Congressionally Mandated Deadline to Publish Cannabinoid Lists
If the FDA can’t even define which cannabinoids are legal, the hemp CBD products you rely on could disappear without warning when the November 2026 ban takes effect. The FDA has missed its Feb 10 deadline to publish lists of naturally occurring cannabinoids, THC-class compounds, and those with ‘similar effects.’ The lists were mandated by Congress under the Nov 2025 spending bill. HHS told reporters it intended to meet the deadline, but nothing has materialized.